| |
| |
Transfer Factor
1. Lawrence HS. The transfer in humans of delayed sensitivity to
Sreptococcal M substance and tuberculin with disrupted
leukocytes. J Clin Invest 34:219-232, 1955.
2. Kahn A, Nagata K, hill No. et al. Management of viral
infections with transfer factor. In Kahn A, Kirkpatrick CH, Hill
NO, eds. Immune regulators in transfer factor. New York:
Academic Press, 501-511, 1974.
3. Shulman ST, Hutio JH, Scott B. Transfer factor therapy of
chronic aggressive hepatitis. In Archer MS, Gottlieb AA,
Kirkpatrick CH, eds. Transfer factor. Basic properties and
clinical applications. New York: Academic Press, 439-448, 1976.
4. Visa D, Vich JM, Phillips J, Rosenfeld F. Orally administered
specific transfer factor for the treatment of herpes infections.
Lymphokine Res. 4:27-30, 1985.
5. Meduri R, Campos E, Scrolli C, et al. Efficacy of transfer
factor in treating patients with recurrent ocular herpes
infections. Biotherapy 9:61-66, 1996.
6. Pizza G, Visa D, De Vinci C. Orally administered HSV-
specific transfer factor prevents genital or labial herpes
relapses. Biotherapy 9:67-72, 1996.
7. Jones JF, Wayburn SJ, Fulgitini VA. Treatment of childhood
combined Epstein Barr virus/ Cytomegalovirus infection with oral
bovine transfer factor. Lancet July 18, 1981.
8. Neequaye J, Viza D, Pizza G, Levine PH, et al. Specific
transfer factor with activity against Epstein- Barr virus
reduces late relapse in endemic Burkitt’s lymphoma. Anti-Canc.
Res. 10:1183-1187, 1990.
9. Parsad U, Bin Jalaludin MA, Rajaduri P, Pizza G, De Vinci C,
Vizza D, Levine PH. Transfer factor with anti- EBV activity as
an adjuvant therapy for nasopharyngeal carcinoma: A pilot study.
Biotherapy 9:109-115,1996.
10. Viza D, Lefesvre A, Patrasco M, et al. A preliminary report
on three AIDS patients treated with Anti- HIV specific transfer
factor. J. Exp. Path. 3:653-659,1987.
11. Viza D. AIDS and transfer factor: Myths, certainties, and
realities. Biotherapy 9:17-26, 1996.
12. Gottlieb AA, Sizemore RC, Gottlieb MS, Kern CH. Rationale
and clinical results for using leukocyte derived
immunosupportive therapies in HIV disease. Biotherapy 9:27-31,
1996.
13. Berron R, Almedarez C, Rosiles G. Suppurative adenopathy by
salmonella B treated with transfer factor. Case report. http:/itfs.med.unibo.it/itfs/
14. Louie E, Borkowsky W, Klesius PH. Treatment of
Cryptosporidiosis with oral bovine transfer factor. Clin.
Immunol. and Immunopath. 44:329-334, 1987.
15. Mc Meeking A, Borkowsky W, Klesius PH, etal. A controlled
trial of bovine dialyzable leukocyte extract for
Cryptosporidiosis in patients with AIDS. J. Inf. Dis.
161:108-112, 1990.
16. Littman BH, Ross ER, Parkman R, etal. Transfer factor-
amphotericin B therapy in case of chronic mucocutaneous
candidiasis. A controlled study. In Archer MS, Gottlieb AA,
Kirkpatrick CH, eds. Transfer factor. Basic properties and
clinical applications. New York: Academic Press, 495, 1976.
17. Ballow M, Hyman L. Immunological reconstitution of chronic
mucocutaneous candidiasis with Transfer factor and fetal thymic
tissue. In Archer MS, Gottlieb AA, Kirkpatrick CH. eds. Transfer
factor. Basic properties and clinical applications. New York:
Academic Press, 501, 1976.
18. Kirkpatrick CH, Greenburg LE. Treatment of chronic
mucoctaneous candidiasis with transfer factor. In Archer MS,
Gottlieb AA, Kirkpatrick CH. eds. Transfer factor. Basic
properties and clinical applications. New York: Academic Press,
547, 1976.
19. Masi M, De Vinci C, Baricorddi OR. Transfer factor in
mucoctaneous candidiasis. Biotherapy. 9: 97-103, 1996.
20. Visa D. Can specific transfer factor be an effective
treatment for CFS? The CFIDS chronicle, Physicians forum Fall,
1993.
21. Levine PH. The use of transfer factor in Chronic Fatigue
Syndrome: Prospects and problems. Biotherapy. 9: 77-79, 1996.
22. De Vinci C, Levine PH, Pizza G. et al. Lessons from pilot
study of transfer factor in Chronic Fatigue Syndrome.
Biotherapy, 9: 87-90, 1996.
23. Hana I, Vrubel J, Pekarek J and Cech K. The influence of age
on transfer factor treatment of cellular immunodeficiency,
Chronic Fatigue Syndrome and /or chronic viral infections.
Biotherapy. 9: 91-95, 1996.
24. Whitaker JA, Dopson MH, Mattman LH. et al. Preliminary study
of transfer factor ( T.F.) in patients with Fibromyalgia (Fm),
Chronic Fatigue Syndrome (Cf), and concomitant Lyme Borreliosis.
http://itfs. med.unibo.it/itfs/
25. Youdim S, Rea WJ, Liang CH. Treatment of environmentally
sensitive patients with transfer factor. Part I: Immunologic
studies. Clin.Ecol. 7:55-61, 1990.
26. Youdim S, Rea WJ. Treatment of environmentally sensitive
patients with transfer factor. Part II: Clinical studies and
immunological correlates. 7: 62-66, 1990.
27. Youdim S, Liang CH, Rea WJ. Treatment of of environmentally
sensitive patients with transfer factor. Part III: Case studies
on three patients. 7: 67-72,1990.
28. Navaro-Cruz D, Serrano–Miranda E, Orea-s s. et al. Transfer
factor as a good therapeutic agent in moderate and severe atopic
dermatitis. http://itfs.med.unibo.it/itfs/
29. Cordero-Miranda MA. Serrano–Miranda E. Flores-Sandoval G. et
al. Treatment of atopic dermatitis with transfer factor and
cyclosporine A. http://itfs.med.unibo.it/itfs/
30. Jones JF, Jeter WS, Hicks MJ, et al. Oral transfer factor (OTF)
use in the hyper IgE syndrome. In Kirkpatrick CH, Brger DR,
Lawrence HS,. eds. Immunobiology of transfer factor. New York:
Academic Press, 261-269, 1983.
31. Ayla-De La Cruz MC, Rodrirguez-Padilla C, Tamaz Guerra R.
Management of hypereosinophilia with transfer factor. http://itfs.med.unibo.it/itfs/
32. Fudenberg HH. Strlkauskas AJ. Goust JM. et al. Discoid lupus
erythmatosus: Dramatic clinical and immunological response to
dialyzable leukotcyte extract (transfer factor) Trans. Assoc.
Am. Phys. 94: 279-291, 1981.
33. Grohn P, Raimo A, Krohn K. The effect of chromatographically
purified Transfer factor component on juvenile Rheumatoid
Arthritis. In Archer MS, Gottlieb AA, Kirkpatrick CH. eds.
Transfer factor. Basic properties and clinical applications.
New York: Academic Press, 613, 1976.
34. Cozine WS, Stanfield AB, Stephens C.A.L. Transfer factor
immunotherapy of Rheumatoid Arthritis. In Archer MS, Gottlieb
AA, Kirkpatrick CH. eds. Transfer factor. Basic properties and
clinical applications. New York: Academic Prss, 617, 1976.
35. McLeod JG, Basten A, Pollard JD. et al. Transfer factor in
the treatment of multiple sclerosis. Clin. Exp. Neurol. 17: 240,
1980.
36. Nevismal O, Pekarek J, Koubek K, et al. Low molecular
transfer factor and it’s use in the treatment of amyotrophic
lateral sclerosis. Cesk. Neurol. Nerochir. 54: 220-223, 1990.
37. Khan A, Hill JM, Piga S, Antone Hi AL. Transfer factor in
Guillian-Barre syndrome. Arch. Neurol. 36: 1997.
38. Fudenberg. HH. Dialyzable lymphocyte extract (DlyE) in
infantile onset autism: A pilot study. Biotherapy. 9: 143-147,
1996.
Colostrum
39. Korhonen H, Syvaoja EL, Ahola-Luttila H, etal. Bactericidal
effect of bovine normal and immune serum, colostrum and milk
against Helicobacter pylori. (6): 655-662, 1995.
40. Rump JA, Aondt R, Arnold A, et al. Treatment of diarrhea in
human immunodeficiency virus infected patients with
immunoglobulins from bovine colostrum. Clin Investigator 70:
588-94, 1992.
41. Flanigan T., Marshal R., Rodman D. et al. In vitro screening
of therapeutic agents against Cryptosporidium: hyperimmune cow
colostrum is highly inhibitory. J. Protozoology 38: 225 S-227 S,
1991.
42. Stephan W., Dichtelmuller H., Lisser R. Antibodies from
colostrum in oral immunotherapy. J. Clin. Chem. And Clin.
Biochem. 28: 19-23, 1990. Cytokines
43. Przmioslo RT, Cliclitera PJ. Cytokines and gastrointestinal
disease mechanisms. Bailieres Clin Gastroenterol 10: 17-32,
1996.
44. Garofalo RP, Glodman AS. Cytokines, Chemokines, and colony
stimulating factors in human milk: the 1997 update. Biol Neonate
74: 134-142, 1998.
45. Dinarello CA. The interleukin-1 family: 10 years of
discovery. FASEB J 8:1314-1325, 1994.
46. Kanderfer S. In vitro and In vivo intereferon production by
Bovine colostrol leukocytes. DTSCH Tierartzl, Wochenschr. 98:
395- 398, 1991.
47. Lawton JW etal. Interferon synthesis by human colostrol
leukocytes. Arch Dis child. 54: 127-130, 1979.
Lactoferrin
48. Nikawa H, Samaranayke LP, Tenovuo J. the fungicidal effect
of human lactorferrin on Candida albicans and Candida krusei.
Archives of oral biology. 38: 1057-1063, 1997.
49. Bellamy W. Wakaboyashi H, Takase M. et al. Killing of
Candida albicans by lactoferrin B, a potent antimicrobial
peptide derived from the N- terminal region of bovine
lactoferrin. Med. Microb and Immunal. 182: 97- 105, 1993.
50. Hasegawo K, Motsuki W, Tanaka S, et al. Inhibition with
lactroferrin of in vitro infection with human herpes virus.
Japanese J. Med. Sci. and Bio. 47: 73-85, 1994.
51. Martin C, Harmsen PJ, Swart MP, et al. Antiviral effects of
plasma and milk proteins: Lactoferrin shows potent activity
against the human immunodeficiency virus and human
cytomegalovirus replication in vitro. J. Infections Dis.
172:380-383, 1995.
52. Togawa J, Nagase H, Tanaka K. et al. Oral administration of
lactoferrin reduces colitis via modulation of immune system and
correction of cytokine imbalance. J. Gastroenterol. Hepatol. 17:
1291-1298, 2002.
53. Tagowa J, Nagase H, Tanaka K. et al. Lactoferrin reduces
colitis in rats via modulation of the immune system and
correction of cytokine imbalance. Am. J. Physiol. Gastrointest.
Liver Physiol. 283: 187-195, 2002.
54. Harversen L A, Baltzer L, Dolphin G. et al.
Anti-inflammatory activities of human lactoferrin in acute
dextran suphate-induced colitis in mice. Scand J. Immunol.
57:2-10, 2003.
Growth Factors
55. Read LC, Francis GL, Wallace JC, Ballard FJ. Growth factor
concentrations and growth- promoting activity in human milk
following premature birth. J Dev Physiol 7: 135-145, 1985.
56. Koldovsky O, Britton J, Davis D, et al. The developing
gastrointestinal tract and milk-borne epidermal growth factor.
In: Mestecky J, ed. Immunology of milk and neonate. New York:
Plenum Press, 99-105, 1991.
57. Cartlidge SA, Elder JB. Transforming growth factor alpha and
EGF levels in normal human gastrointestinal mucosa. Br J Cancer
60: 657-660, 1989.
58. Koyama S, Podolsky DK. Differantial expression of
transforming growth factors alpha and beta in rat intestinal
epithelial cells. J Clin Invest 83: 1768-1773, 1989.
59. Shing YW, Klagsbrun M. human and bovine milk contain
different set of growth factors. Endocinology 115: 273-282,
1984.
60. Siafakas CG, Anatolitou F, Funsunyan RD, Walker WA,
Sanderson IR. Vascular endothelial growth factor (VEGF) is
present in human breast milk and its receptor is present on
intestinal epithelial cells. Pediatr. Res. 45:652-657, 1999.
B1,3/1,6 Glucan
61. Manners DJ, Mason AJ, Patterson JC. The structure of B-
(1-3) glucan from yeast cell walls. Biochem. J. 135: 19-30,
1973.
62. DiLuzio NR, McNaffec R, Jones E, et al. The employment of
glucan and glucan activated macrophages in enhancement of host
resistance to malignancies in experimental animals. In: MD Fink
(ed) the macrophage in Neoplasia. 121-198, Academic Press, New
York,1976.
63. Diluzio NR, Williams DL, McNamee TLB, et al. Comparative
tumor-inhibotory and anti bacterial activity of soluble and
particulate glucan. Int. J, Cancer 24: 773-779, 1979.
64. Patchen ML, Macvittie TJ, Brook I. Glucan- induced
hemopoietic and immune stimulation: therapeutic effects in
sub-lethally and lethally irradiated mice. Methods Find Exp Clin
Pharmacol 8:151-155, 1986.
65. Abel G, Czop JC. Stimulation of human monocy te beta- glucan
receptors by glucan particles induces production of TNF- alpha
and IL- I beta. Int. J. Immunopharmoc 14:1363-1373, 1992.
66. Macela A, Lesna J, Kovarovou H. modulatory effect of glucans
on the function of murine macrophages, NK- cells and
lymphocytes. Bratise Lek Listy 92: 283-290, 1991. Chicken Egg
Chicken Egg Yolk Antibody (IgY)
67. Loch U, Schranner I, Wanke R, et al. The chicken egg and
antibody source. J. Vet. Med B 33: 609-919, 1986.
68. Peralta RC, Yokoyama H, Ikemori Y. et al. Passive
immunization against salmonellosis in mice by orally
administered hen egg yolk antibodies specific for 14-KD a
fimbriae of salmonella enderitidis. J. Med. Microbiol 41: 29-35,
1994.
69. Ikemori Y, Ohta M, Umeda K, et al. Passive protection of
neonatal calves against bovine corona virus- induced diarrhea by
administration of egg yolk or colostrum antibody powder. Vet.
Microbiol. 58: 105-111, 1997.
70. Schmidt P, Wiedmann V, Kuhlmann R, et al. Chicken egg
antibodies for prophylaxis and therapy of infectious intestinal
diseases. II. In vitro studies on gastric and enteric digestion
of egg yolk antibodies specific against pathogenic Eschorichia
coli strains. J. Vet. Med B 36: 619- 628, 1989.
71. Shimizu M, Fitzsimmons RC, Nakai S, Anti E. coli
immunoglobulin Y isolated fromm egg yolk of immunized chickens
as a potential food ingredient. J. Food Sci 53: 1360-1366: 1988.
72. Yolken RH, Leister F, Wee S-B, et al. Antibodies to Rota
viruses in chicken eggs. A potential source of antiviral
immunoglobulins suitable for human consumption. Pediatrics 82:
291-295, 1988.
73. Hatta H, Tsuda K, Ozaki M, et al. Passive immunization
against dental plaque formation in humans: Effect of a mouth
rinse containing egg yolk antibodies (IgY) specific for
Strepcoccus mutans, Carrier Res 31: 268- 274, 1997.
Inflammatory Cytomines - TNF
74. Komatsu M, Kobayashi D, Saito K. et al. Tumor necrosis
factor-alpha in serum of patients with inflammatory bowel
disease as measured by a highly sensitive immuni-PCR, Clin.
Chem. 47:1297-1301, 2001.
75. Louis E. The immuno-inflammatory reaction in Crohn's disease
and ulcerative colitis: Characterisation, genetics and clinical
application. Focus on TNFalpha. Acta. Gastroenterol. Belg.
64:1-5, 2001.
76. Hommes DW, van Deventer S J. Targeting tumor necrosis factor
alpha in inflammatory bowl disease: Why, how and when? Curr.
Opin. Gastroenterol. 19:350-357, 2003.
TNF inhibitors and
Antibodies
77. Blam E M, Stein R B, Lichtenstein G R. Integrating
anti-tumor necrosis factor therapy in inflammatory bowl disease.
Current and future perspectives. Am. J. Gastroenterol.
96:1977-1997, 2001.
78. Ganesan S, Travis SP, Ahmad T, Jazrawi R. Therapeutic
inhibitors of tumor necrosis factor in Crohn's disease. Curr.
Open. Investig. Drugs. 3:1301-1306, 2002.
79. Mamula P, Cohen SA, Ferry G D et al. CDP571, a humanized
anti-tumor necrosis factor aloha monoclonal antibody in
pediatric Crohn's disease. Inflamm. Bowel Dis 10:723-730, 2004.
80. Rutgeerts PJ, D'Haens G, Targan S. et al. Efficacy and
safety of treatment with anti-tumor necrosis factor antibody (infliximab)
to maintain remission in Crohn's disease. Gastroenterology
117:761-769, 1999.
81. Worledge KL, Godiska R, Terrence A. et al. Oral
administration of avian tumor necrosis factor antibodies
effectively treats experimental colitis in rats. Digestive
disease and Sciences 45: 2298-2305, 2000.
|
|
|
|